Cigna Investments Inc. New cut its stake in shares of C.R. Bard, Inc. (NYSE:BCR) by 6.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,868 shares of the medical instruments supplier’s stock after selling 182 shares during the period. Cigna Investments Inc. New’s holdings in C.R. Bard were worth $907,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fundsmith LLP increased its position in C.R. Bard by 2.1% in the first quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock worth $633,996,000 after buying an additional 52,272 shares in the last quarter. Creative Planning increased its position in C.R. Bard by 0.7% in the first quarter. Creative Planning now owns 4,298 shares of the medical instruments supplier’s stock worth $1,068,000 after buying an additional 29 shares in the last quarter. Granite Investment Advisors LLC increased its position in C.R. Bard by 14.3% in the first quarter. Granite Investment Advisors LLC now owns 33,276 shares of the medical instruments supplier’s stock worth $8,270,000 after buying an additional 4,159 shares in the last quarter. Buffington Mohr McNeal increased its position in C.R. Bard by 14.1% in the first quarter. Buffington Mohr McNeal now owns 7,545 shares of the medical instruments supplier’s stock worth $1,875,000 after buying an additional 930 shares in the last quarter. Finally, Huntington National Bank increased its position in C.R. Bard by 8.4% in the first quarter. Huntington National Bank now owns 16,411 shares of the medical instruments supplier’s stock worth $4,079,000 after buying an additional 1,278 shares in the last quarter. 85.32% of the stock is owned by hedge funds and other institutional investors.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at 319.75 on Friday. The stock has a market cap of $23.24 billion, a PE ratio of 41.98 and a beta of 0.59. The stock’s 50 day moving average price is $319.00 and its 200-day moving average price is $283.44. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $323.27.

C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The company had revenue of $979.70 million during the quarter, compared to the consensus estimate of $976.53 million. During the same period last year, the business earned $2.54 EPS. The business’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts predict that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Friday, August 4th. Stockholders of record on Monday, July 24th were paid a dividend of $0.26 per share. This represents a $1.04 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date was Thursday, July 20th. C.R. Bard’s dividend payout ratio (DPR) is presently 13.67%.

WARNING: “Cigna Investments Inc. New Has $907,000 Position in C.R. Bard, Inc. (NYSE:BCR)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/08/12/cigna-investments-inc-new-has-907000-position-in-c-r-bard-inc-nysebcr.html.

A number of research analysts have recently commented on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 price objective for the company in a research note on Tuesday, June 13th. BidaskClub downgraded shares of C.R. Bard from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 19th. Morgan Stanley downgraded shares of C.R. Bard from an “overweight” rating to an “equal weight” rating in a research note on Monday, April 24th. Jefferies Group LLC upped their price objective on shares of C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a research note on Monday, April 24th. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research note on Tuesday, July 11th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $285.67.

In other news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.80% of the stock is owned by company insiders.

About C.R. Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.